×
OnKure Therapeutics EBIT 2020-2024 | OKUR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
OnKure Therapeutics ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
OnKure Therapeutics EBIT 2020-2024 | OKUR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
OnKure Therapeutics ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$88.1B
Takeda Pharmaceutical (TAK)
$44.8B
Merck (MKGAF)
$21.8B
Astellas Pharma (ALPMY)
$20.6B
Sandoz Group AG (SDZNY)
$18.4B
Summit Therapeutics (SMMT)
$17B
United Therapeutics (UTHR)
$16.5B
Shionogi (SGIOY)
$12.2B
Neurocrine Biosciences (NBIX)
$12B
Catalent (CTLT)
$10.9B
Orion OYJ (ORINY)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$7.1B
Ionis Pharmaceuticals (IONS)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.5B
Corcept Therapeutics (CORT)
$4.9B
Crinetics Pharmaceuticals (CRNX)
$4.7B
Madrigal Pharmaceuticals (MDGL)
$4.7B
Dyne Therapeutics (DYN)
$3.6B
PTC Therapeutics (PTCT)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Soleno Therapeutics (SLNO)
$2.1B
Recursion Pharmaceuticals (RXRX)
$2B
Harrow (HROW)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Ocular Therapeutix (OCUL)
$1.8B
NewAmsterdam Pharma (NAMS)
$1.7B
ARS Pharmaceuticals (SPRY)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B